Stent Designed Specifically for Bifurcations

A new coronary stent being developed for the treatment of bifurcation lesions has been used clinically for the first time.

The Tryton side-branch stent, being developed by Tryton Medical (Newton, MA, USA), is designed to treat coronary artery arterial lesions involving a bifurcation. The stent is a unique balloon expandable, 5 French compatible system that is delivered with a single wire. When used in conjunction with any existing standard stent for the main vessel, it provides superior coverage and hoop strength to the origin of the side-branch. The Tryton side branch stent is currently for investigational use only.

Coronary artery disease located at the branch of arteries occurs in up to 25% of patients currently undergoing coronary stenting. However, the designs of available drug-eluting stents do not adequately address this group of patients. Stents placed at bifurcations are currently associated with higher acute complications as well as late restenosis.

"These cases demonstrate that a Tryton stent strategy provides a simple and easy way to treat complex bifurcation lesions with beautiful results, said Professor Eberhard Grube, M.D, who directed the first clinical use of the stent at the Heart Center in Siegburg (Germany).

The Tryton first-in-man study is a multi-center clinical trial evaluating the utility of the Tryton side-branch stent. The study is being performed at the Institute Cardiovascular Paris Sud (France) and the Heart Center in Siegburg.



Related Links:
Tryton Medical